Loteprednol etabonate - CAS 82034-46-6
Catalog number: B0084-077918
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Glucocorticoid Receptor
Loteprednol etabonate is an anti-inflammatory corticosteroid used in ophthalmology.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-077918 1 g $199 In stock
Bulk Inquiry
ONO-2235; ONO2235; ONO2235; Loteprednol Etabonate; Lotemax; Alrex; HGP-1; Loterox; Locort
Canonical SMILES:
1.Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED).
Sy A1,2, O'Brien KS3, Liu MP4, Cuddapah PA5, Acharya NR6,7, Lietman TM8,9, Rose-Nussbaumer J10,11. BMC Ophthalmol. 2015 Oct 13;15:133. doi: 10.1186/s12886-015-0122-z.
BACKGROUND: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in newer therapies.
2.A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery.
Salinger CL1, Gordon M2, Jackson MA3, Perl T4, Donnenfeld E5. Clin Ophthalmol. 2015 Nov 6;9:2089-97. doi: 10.2147/OPTH.S94332. eCollection 2015.
BACKGROUND: While loteprednol etabonate ophthalmic gel 0.5% (LE gel) is approved for treatment of postoperative ocular inflammation and pain, there have been no reported studies in patients undergoing laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK).
3.Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
Sheppard JD1, Comstock TL2, Cavet ME3. Adv Ther. 2016 Mar 17. [Epub ahead of print]
Corticosteroids are a mainstay therapeutic option for the treatment of ocular inflammation. However, safety remains a concern for clinicians, particularly with long-term use. Though highly effective at suppressing inflammatory and allergic responses, topical ophthalmic corticosteroids carry an inherent risk of side effects, including elevated intraocular pressure (IOP), a risk factor for the development of glaucoma. The corticosteroid loteprednol etabonate (LE) contains an ester rather than a ketone at the C-20 position, minimizing the potential for side effects, including IOP elevation. In early pivotal clinical trials of LE ophthalmic suspension for conjunctivitis (allergic, giant papillary), anterior uveitis, and post-operative inflammation, LE had minimal impact on IOP over short-term (<28 days) and long-term (≥28 days) use. Since then, new LE formulations-including a gel, an ointment, and a suspension of LE in combination with tobramycin-have become commercially available.
4.Design, characterization and in vitro evaluation of novel shell crosslinked poly(butylene adipate)-co-N-succinyl chitosan nanogels containing loteprednol etabonate: A new system for therapeutic effe
Nasr FH1, Khoee S2. Eur J Med Chem. 2015 Sep 18;102:132-42. doi: 10.1016/j.ejmech.2015.07.045. Epub 2015 Aug 1.
This study reports on the development of a novel mucoadhesive and biocompatible shell-crosslinked nanogel system based on poly(butylene adipate) (PBA) and N-succinyl chitosan (S-Cs) by coupling reaction with a new formulation method. For this purpose, two different molecular weights of dendrimerized PBA with amine terminated functional groups were synthesized separately and characterized well by FT-IR, (1)HNMR and GPC. The PBA nanoparticles containing loteprednol etabonate (LPE) prepared by O/W emulsion technique were reacted immediately with modified carboxylated chitosan via carbodiimide chemistry. TEM photographs of the nanoparticles and crosslinked nanoparticles displayed a spherical morphology closely corresponding to the results obtained by DLS. On The other hand, biodegradability, biocompatibility and bioadhesiveness of the prepared nanoparticles were also studied. It is concluded that the core-shell structured nanogels can be used as novel ocular drug delivery systems with appropriate loading capacity for slightly water soluble LPE as an anti-inflammatory drug.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Glucocorticoid Receptor Products


A glucocorticoid receptor modulator.

CAS 50-02-2 Dexamethasone

(CAS: 50-02-2)

Dexamethasone is a glucocorticoid with anti-inflammatory activity that reduces levels of activated NF-κB in immature dendritic cells (DCs) and inhibits differen...


CHF-6162 is an agonist of glucocorticoid receptor (GR) (IC50 = 0.24nM), which shows greater potency than fluticasone and budesonide in a radioligand binding ass...

CAS 397864-44-7 Fluticasone furoate

Fluticasone furoate
(CAS: 397864-44-7)

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone as a selective high affinity glucocorticoid agonist, MRP4 inhibitor;

CAS 152-58-9 Cortodoxone

(CAS: 152-58-9)

Cortodoxone, a glucocorticoid receptor antagonist, is an intermediate which can be oxygenated to cortisol.

CAS 126544-47-6 Ciclesonide

(CAS: 126544-47-6)

Ciclesonide, a glucocorticoid, could be useful in the treatment of sorts of airway inflammatory diseases like allergic rhinitis.

CAS 3385-03-3 Flunisolide

(CAS: 3385-03-3)

Flunisolide is a corticosteroid and used for the treatment of allergic rhinitis.

CAS 378-44-9 Betamethasone

(CAS: 378-44-9)

Betamethasone is a potent glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Unlike other drugs with these effects, betamethasone d...

Chemical Structure

CAS 82034-46-6 Loteprednol etabonate

Quick Inquiry

Verification code

Featured Items